Last reviewed · How we verify
NY-ESO-1 ISCOMATRIX®
At a glance
| Generic name | NY-ESO-1 ISCOMATRIX® |
|---|---|
| Sponsor | Ludwig Institute for Cancer Research |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
- Injection site pain
- Lethargy
- Fatigue
- Influenza like illness
- Pain in extremity
- Dyspnoea
- Injection site erythema
- Headache
- Myalgia
- Vomiting
- Upper respiratory tract infection
- Dizziness
Key clinical trials
- Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma (PHASE2)
- Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |